[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:gtpase-kras":3},{"name":4,"total":5,"recruiting":6,"trials":7},"GTPase KRas",105,95,[8,16,23,29,36,42,48,54,60,67,73,79,85,92,98,104,110,116,122,128,134,139,144,150,155,161,167,173,179,185,191,197,203,209,215,221,227,233,239,245,250,256,262,268,274,280,285,291,297,302],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT07252739","KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J\u002FKEYMAKER-U01J)",[12],"Phase 2","RECRUITING","2026-08-26T02:16:09.452956Z","2026-07-30T01:46:14.436674Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07286149","A Clinical Study of MK-1084 With Other Treatments for Non-small Cell Lung Cancer (MK-3475-01F)",[20],"Phase 1\u002FPhase 2","2026-08-26T02:18:21.216897Z","2026-07-24T01:27:14.895684Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT05874414","Combination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma",[20],"2026-08-26T02:17:33.807405Z","2026-07-19T19:36:05.120159Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT06890598","Study of Olomorasib (LY3537982) in Combination With Standard of Care in Participants With Resected or Unresectable KRAS G12C-mutant Non-Small Cell Lung Cancer",[33],"Phase 3","2026-08-26T02:19:13.549512Z","2026-07-19T19:36:05.058056Z",{"nct_id":37,"title":38,"phases":39,"status":13,"updated_at":40,"content_modified":41},"NCT06412198","A Multicenter Phase 1b\u002F2 Study of Adagrasib, Cetuximab, and Cemiplimab for Metastatic Colorectal Cancer Harboring KRAS G12C Mutations",[20],"2026-08-26T02:16:26.411851Z","2026-07-05T05:32:16.754256Z",{"nct_id":43,"title":44,"phases":45,"status":13,"updated_at":46,"content_modified":47},"NCT06411821","Ulixertinib in People With Histiocytic Neoplasms",[12],"2026-08-26T02:17:05.997056Z","2026-07-05T05:32:16.753306Z",{"nct_id":49,"title":50,"phases":51,"status":13,"updated_at":52,"content_modified":53},"NCT06997497","A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012\u002FKANDLELIT-012)",[33],"2026-08-26T02:16:02.918558Z","2026-07-05T05:32:16.725184Z",{"nct_id":55,"title":56,"phases":57,"status":13,"updated_at":58,"content_modified":59},"NCT07566052","A Study to Compare Setidegrasib (ASP3082) With Docetaxel, in People With Non-small Cell Lung Cancer With a KRAS G12D Mutation",[33],"2026-08-26T02:19:25.538428Z","2026-07-05T05:32:16.686769Z",{"nct_id":61,"title":62,"phases":63,"status":13,"updated_at":65,"content_modified":66},"NCT07318324","Phase Ib Study of Avutometinib, Defactinib, and Everolimus in RAS Pathway Mutant Endometrial Cancer",[64],"Phase 1","2026-08-26T02:17:46.653867Z","2026-07-05T05:32:16.676290Z",{"nct_id":68,"title":69,"phases":70,"status":13,"updated_at":71,"content_modified":72},"NCT07671339","A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer",[64],"2026-08-26T02:15:51.395565Z","2026-07-05T03:45:20.372123Z",{"nct_id":74,"title":75,"phases":76,"status":13,"updated_at":77,"content_modified":78},"NCT07535112","A Study to Learn More About How Safe BAY 3771249 is and How Well it Works in People With Advanced or Metastatic Colorectal Cancer That Has a KRAS G12D Mutation",[64],"2026-08-26T02:17:33.002248Z","2026-06-18T12:24:02.327259Z",{"nct_id":80,"title":81,"phases":82,"status":13,"updated_at":83,"content_modified":84},"NCT04302025","A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)",[12],"2026-08-26T02:16:08.402952Z","2026-06-16T05:54:07.906610Z",{"nct_id":86,"title":87,"phases":88,"status":13,"updated_at":90,"content_modified":91},"NCT04613596","Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of Adagrasib in Combination in Patients With a KRAS G12C Mutation KRYSTAL-7",[89],"Phase 2\u002FPhase 3","2026-08-26T02:16:20.336282Z","2026-06-16T05:54:07.905720Z",{"nct_id":93,"title":94,"phases":95,"status":13,"updated_at":96,"content_modified":97},"NCT07621718","Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )",[33],"2026-08-26T02:17:38.215063Z","2026-06-04T01:30:07.905536Z",{"nct_id":99,"title":100,"phases":101,"status":13,"updated_at":102,"content_modified":103},"NCT07554339","A Clinical Trial of Calderasib (MK-1084) and Durvalumab in People With Non-Small Cell Lung Cancer (MK-1084-015\u002FKANDLELIT-015)",[33],"2026-08-26T02:15:44.309045Z","2026-06-04T01:30:07.902092Z",{"nct_id":105,"title":106,"phases":107,"status":13,"updated_at":108,"content_modified":109},"NCT06072781","A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer",[33],"2026-08-26T02:19:07.104270Z","2026-05-05T02:43:29.672217Z",{"nct_id":111,"title":112,"phases":113,"status":13,"updated_at":114,"content_modified":115},"NCT06619587","A Study to Evaluate Safety, Pharmacokinetics, and Activity of GDC-7035 as a Single Agent and in Combination in Patients With Advanced Solid Tumors",[64],"2026-08-26T02:17:43.321968Z","2026-05-05T02:43:29.509157Z",{"nct_id":117,"title":118,"phases":119,"status":13,"updated_at":120,"content_modified":121},"NCT06343402","Open-label Study of BBO-8520 in Adult Subjects With KRASG12C Non-small Cell Lung Cancer",[64],"2026-08-26T02:17:58.890423Z","2026-05-05T02:43:29.059683Z",{"nct_id":123,"title":124,"phases":125,"status":13,"updated_at":126,"content_modified":127},"NCT05410145","A Study of D3S-001 Monotherapy or Combination Therapy in Subjects With Advanced Solid Tumors With a KRAS p.G12C Mutation",[20],"2026-08-26T02:17:03.534765Z","2026-05-05T02:43:29.047352Z",{"nct_id":129,"title":130,"phases":131,"status":13,"updated_at":132,"content_modified":133},"NCT07456046","A Phase 1 Study of D3S-003 as Monotherapy in Participants With Advanced Solid Tumors With a KRAS p.G12D Mutation.",[64],"2026-08-26T02:19:27.519777Z","2026-05-05T02:43:29.026378Z",{"nct_id":135,"title":136,"phases":137,"status":13,"updated_at":58,"content_modified":138},"NCT06495125","Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung Cancer",[12],"2026-05-05T02:43:28.885333Z",{"nct_id":140,"title":141,"phases":142,"status":13,"updated_at":65,"content_modified":143},"NCT06504459","Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML",[12],"2026-05-05T02:43:28.882922Z",{"nct_id":145,"title":146,"phases":147,"status":13,"updated_at":148,"content_modified":149},"NCT04858009","Hyperthermic Intraperitoneal Chemotherapy for the Treatment of Pancreatic Cancer and Peritoneal Metastasis",[12],"2026-08-26T02:18:00.873391Z","2026-05-05T02:43:28.851444Z",{"nct_id":151,"title":152,"phases":153,"status":13,"updated_at":52,"content_modified":154},"NCT05789082","A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation",[20],"2026-05-05T02:43:28.825043Z",{"nct_id":156,"title":157,"phases":158,"status":13,"updated_at":159,"content_modified":160},"NCT06096974","Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS",[64],"2026-08-26T02:19:20.945539Z","2026-05-05T02:43:28.566526Z",{"nct_id":162,"title":163,"phases":164,"status":13,"updated_at":165,"content_modified":166},"NCT07172919","A Rollover Study Evaluating Sotorasib With or Without Panitumumab in Participants With KRAS p.G12C Mutation",[12],"2026-08-26T02:15:01.639696Z","2026-05-05T02:43:28.558810Z",{"nct_id":168,"title":169,"phases":170,"status":13,"updated_at":171,"content_modified":172},"NCT06345729","A Study of Calderasib (MK-1084) Plus Pembrolizumab (MK-3475) in Participants With KRAS G12C Mutant Non-small Cell Lung Cancer (NSCLC) With Programmed Cell Death Ligand 1 (PD-L1) Tumor Proportion Score (TPS) ≥50% (MK-1084-004\u002FKANDLELIT-004)",[33],"2026-08-26T02:15:09.079045Z","2026-05-05T02:43:28.402965Z",{"nct_id":174,"title":175,"phases":176,"status":13,"updated_at":177,"content_modified":178},"NCT06336902","Botensilimab Plus Balstilimab and Fasting Mimicking Diet Plus Vitamin C for Patients With KRAS-Mutant Metastatic Colorectal Cancer",[64],"2026-08-26T02:16:55.892527Z","2026-05-05T02:43:28.371310Z",{"nct_id":180,"title":181,"phases":182,"status":13,"updated_at":183,"content_modified":184},"NCT07030959","Study of AUBE00 in Patients With Solid Tumors",[64],"2026-08-26T02:19:23.493898Z","2026-05-05T02:43:28.191330Z",{"nct_id":186,"title":187,"phases":188,"status":13,"updated_at":189,"content_modified":190},"NCT06152809","CIML NK Cells With Venetoclax for AML",[64],"2026-08-26T02:15:47.754948Z","2026-05-05T02:43:28.162326Z",{"nct_id":192,"title":193,"phases":194,"status":13,"updated_at":195,"content_modified":196},"NCT06745908","Randomized, Two-Cohort, Open-Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In",[33],"2026-08-26T02:18:42.501841Z","2026-05-05T02:43:28.120702Z",{"nct_id":198,"title":199,"phases":200,"status":13,"updated_at":201,"content_modified":202},"NCT05815173","Ladarixin With Sotorasib in Advanced NSCLC",[64],"2026-08-26T02:19:15.498463Z","2026-05-05T02:43:27.747385Z",{"nct_id":204,"title":205,"phases":206,"status":13,"updated_at":207,"content_modified":208},"NCT07204340","TLN-372 in Advanced KRAS Mutant Solid Tumors",[64],"2026-08-26T02:15:27.567165Z","2026-05-05T02:43:27.444808Z",{"nct_id":210,"title":211,"phases":212,"status":13,"updated_at":213,"content_modified":214},"NCT06797336","A Study of PT0253 in Participants With KRAS G12D Mutated Advanced Solid Tumors",[64],"2026-08-26T02:18:17.007929Z","2026-05-05T02:43:27.435980Z",{"nct_id":216,"title":217,"phases":218,"status":13,"updated_at":219,"content_modified":220},"NCT07522073","A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma",[33],"2026-08-26T02:17:19.710918Z","2026-05-05T02:43:27.421423Z",{"nct_id":222,"title":223,"phases":224,"status":13,"updated_at":225,"content_modified":226},"NCT07021898","A Study of ERAS-4001 in Patients With Advanced or Metastatic Solid Tumors.",[64],"2026-08-26T02:19:21.761002Z","2026-05-05T02:43:27.258450Z",{"nct_id":228,"title":229,"phases":230,"status":13,"updated_at":231,"content_modified":232},"NCT06720987","A Study to Investigate the Safety and Efficacy of KQB365 as Monotherapy and in Combination in Participants With Advanced Solid Malignancies",[64],"2026-08-26T02:16:54.876240Z","2026-05-05T02:43:27.252443Z",{"nct_id":234,"title":235,"phases":236,"status":13,"updated_at":237,"content_modified":238},"NCT04929223","A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC)",[64],"2026-08-26T02:16:32.589113Z","2026-05-05T02:43:27.095505Z",{"nct_id":240,"title":241,"phases":242,"status":13,"updated_at":243,"content_modified":244},"NCT07190248","A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007\u002FKANDLELIT-007)",[33],"2026-08-26T02:17:07.954622Z","2026-05-05T02:43:27.068039Z",{"nct_id":246,"title":247,"phases":248,"status":13,"updated_at":52,"content_modified":249},"NCT07247110","A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)",[64],"2026-05-05T02:43:26.975571Z",{"nct_id":251,"title":252,"phases":253,"status":13,"updated_at":254,"content_modified":255},"NCT05254184","KRAS-Targeted Vaccine With Chemoimmunotherapy, Nivolumab and Ipilimumab for Patients With NSCLC",[64],"2026-08-26T02:18:38.865010Z","2026-05-05T02:43:26.935725Z",{"nct_id":257,"title":258,"phases":259,"status":13,"updated_at":260,"content_modified":261},"NCT06162221","Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC",[20],"2026-08-26T02:18:51.833592Z","2026-05-05T02:43:26.935632Z",{"nct_id":263,"title":264,"phases":265,"status":13,"updated_at":266,"content_modified":267},"NCT05661201","NEROFE and Doxorubicin in KRAS-mutated ST2-positive Solid Tumors",[64],"2026-08-26T02:17:42.501124Z","2026-05-05T02:43:26.768897Z",{"nct_id":269,"title":270,"phases":271,"status":13,"updated_at":272,"content_modified":273},"NCT03608631","iExosomes in Treating Participants With Metastatic Pancreas Cancer With KrasG12D Mutation",[20],"2026-08-26T02:18:27.904411Z","2026-05-05T02:43:26.686443Z",{"nct_id":275,"title":276,"phases":277,"status":13,"updated_at":278,"content_modified":279},"NCT06807619","A Study of Sotorasib in People With Brain Tumors",[64],"2026-08-26T02:16:38.053590Z","2026-04-29T02:57:57.151752Z",{"nct_id":281,"title":282,"phases":283,"status":13,"updated_at":108,"content_modified":284},"NCT06119581","A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer",[33],"2026-04-29T02:57:57.146513Z",{"nct_id":286,"title":287,"phases":288,"status":13,"updated_at":289,"content_modified":290},"NCT07409272","A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer",[33],"2026-08-26T02:15:25.633039Z","2026-04-29T02:57:57.145671Z",{"nct_id":292,"title":293,"phases":294,"status":13,"updated_at":295,"content_modified":296},"NCT07111520","A Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced Non-small Cell Lung Cancer (NSCLC)",[20],"2026-08-26T02:15:39.267524Z","2026-04-29T02:57:57.062678Z",{"nct_id":298,"title":299,"phases":300,"status":13,"updated_at":278,"content_modified":301},"NCT07594067","TCR1188-ABC Cells in KRAS-mutated Cancers",[64],"2026-07-19T19:36:05.077181Z",{"nct_id":303,"title":304,"phases":305,"status":13,"updated_at":306,"content_modified":307},"NCT05382559","A Study of ASP3082 in Adults With Advanced Solid Tumors",[64],"2026-08-26T02:16:46.951087Z","2026-07-05T05:32:16.801787Z"]